Published in Biotech Business Week, December 27th, 2004
Emisphere is currently engaged in litigation with Eli Lilly and Co. concerning the termination of the existing oral PTH collaboration between the two companies. Novartis has acquired an option to license Emisphere's eligen technology for the development of an oral PTH that is dependent upon,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.